AI Summary
✦ ClarthaValuation Metrics
Trading 42.9% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.02). Confidence: 79%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
128.23
Current
154.62
Overvalued
120.35
Undervalued
91.05
5Y Average
2.16
Current
2.60
Overvalued
2.48
Undervalued
1.83
5Y Average
12.68
Current
15.29
Overvalued
13.25
Undervalued
9.67
Peers & Comparison
No sector data available for this company.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹18 CrMar 2026Latest net profit
₹1.59 CrMar 2026Latest EPS
₹0.80Mar 2026Net margin
18.9%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 7.93 | 10.39 | 8.06 | 10.13 | 9.92 | 12.52 | 10.30 | 11.87 | 8.92 | 8.22 | 10.43 | 16.91 | 18.38 |
| Expenses + | 8.97 | 8.35 | 7.39 | 9.03 | 9.37 | 9.13 | 8.35 | 9.83 | 9.83 | 9.34 | 8.96 | 12.26 | 14.91 |
| Operating Profit | -1.04 | 2.04 | 0.67 | 1.10 | 0.55 | 3.39 | 1.95 | 2.04 | -0.91 | -1.12 | 1.47 | 4.65 | 3.47 |
| OPM % | -13.11% | 19.63% | 8.31% | 10.86% | 5.54% | 27.08% | 18.93% | 17.19% | -10.20% | -13.63% | 14.09% | 27.50% | 18.88% |
| Other Income + | 0.26 | 0.30 | 0.26 | -0.12 | 0.25 | 0.11 | 0.16 | 0.22 | 0.14 | 0.38 | 0.26 | 0.18 | 0.37 |
| Interest | 0.25 | 0.19 | 0.25 | 0.13 | 0.16 | 0.15 | 0.27 | 0.26 | 0.35 | 0.36 | 0.38 | 0.38 | 0.25 |
| Depreciation | 1.37 | 1.42 | 1.38 | 1.35 | 1.41 | 1.28 | 1.25 | 1.23 | 1.53 | 1.50 | 1.45 | 1.35 | 1.36 |
| Profit before tax | -2.40 | 0.73 | -0.70 | -0.50 | -0.77 | 2.07 | 0.59 | 0.77 | -2.65 | -2.60 | -0.10 | 3.10 | 2.23 |
| Tax % | -5.83% | 20.55% | -27.14% | -22.00% | -3.90% | 22.71% | 74.58% | 57.14% | -49.43% | -16.54% | -10.00% | 25.81% | 28.70% |
| Net Profit + | -2.25 | 0.58 | -0.50 | -0.39 | -0.74 | 1.60 | 0.15 | 0.32 | -1.34 | -2.16 | -0.09 | 2.30 | 1.59 |
| EPS in Rs | -1.45 | 0.37 | -0.32 | -0.25 | -0.48 | 1.03 | 0.10 | 0.20 | -0.85 | -1.36 | -0.06 | 1.45 | 0.80 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Intimation Of Approval For Addition Of Beds To The Existing Approved Bioavailability/ Bioequivalence Center Of Jeevan Scientific Technology Limited''s Bioavailability/Bioequivalence.
Information About The Successful Completion Of USFDA Inspection.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Notification Of Inspection For Addition Of Beds To The Existing Approved Bioavailability/Bioequivalence Center Of Jeevan Scientific Technology Limited.